Alector Inc ALEC:NASDAQ

Last Price$6.97NASDAQ Last Trade as of 1:57PM ET 6/01/23
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.47(6.32%)
Bid (Size)$6.96 (4)
Ask (Size)$6.97 (4)
Day Low / High$6.94 - 7.41
Volume134.2 K
  • Latest Stories
  • Commentary and Analysis
--Barclays Adjusts Price Target on Alector to $12 From $14, Maintains Overweight Rating
10:13AM ET 5/05/2023 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Morgan Stanley Adjusts Price Target on Alector to $10 From $11, Maintains Equal-Weight Rating
11:04AM ET 3/03/2023 MT Newswires

Alector (ALEC) has an average outperform rating and a price target range of $6 to $41, according to analysts polled by Capital IQ. (MT Newswires covers...

--BTIG Adjusts Price Target on Alector to $16 From $54, Keeps Buy Rating
10:59AM ET 3/02/2023 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Mizuho Adjusts Price Target on Alector to $12 From $15, Keeps Buy Rating
10:20AM ET 3/02/2023 MT Newswires

Alector (ALEC) has an average rating of outperform and price targets ranging from $6 to $41, according to analysts polled by Capital IQ. (MT Newswires...

Citigroup Adjusts Price Target on Alector to $12 From $17, Maintains Buy Rating
10:45AM ET 3/01/2023 MT Newswires

Alector (ALEC) has an average outperform rating and price target range of $6 to $54, according to analysts polled by Capital IQ. (MT Newswires covers...

Morgan Stanley Adjusts Price Target on Alector to $11 From 13, Maintains Equalweight Rating
8:33AM ET 1/24/2023 MT Newswires

Alector (ALEC) has an average rating of outperform and price targets ranging from $6 to $54, according to analysts polled by Capital IQ. (MT Newswires...

Alector Says Phase 1 Study of AL101 for Neurodegenerative Disease Treatment Shows Elevated Progranulin Levels in Brain
1:41PM ET 11/29/2022 MT Newswires

Alector (ALEC) said Tuesday that its first-in-human phase 1 study of AL101 for the potential treatment of neurodegenerative diseases, including Alzheimer's...

--Citigroup Adjusts Price Target on Alector to $17 From $19, Maintains Buy Rating
10:02AM ET 11/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Alector Initiates Phase 1 Clinical Trial of AL044 to Treat Alzheimer's Disease
8:09AM ET 9/12/2022 MT Newswires

Alector (ALEC) said Monday that it has initiated the first-in-human phase 1 trial of AL044 to treat Alzheimer's Disease. The study is intended to...

Alector Shares Plunge After Morgan Stanley Downgrade
1:49PM ET 9/09/2022 MT Newswires

Alector (ALEC) shares fell nearly 10.5% in Friday afternoon trading after Morgan Stanley downgraded the stock to equalweight from overweight and cut the...